Debra E Lyon1, Angela Starkweather2, Yingwei Yao1, Timothy Garrett3, Debra Lynch Kelly1, Victoria Menzies4, Paweł Dereziński5, Susmita Datta6, Sreelakshmy Kumar1, Colleen Jackson-Cook7. 1. 1 College of Nursing, University of Florida, Gainesville, FL, USA. 2. 2 School of Nursing, University of Connecticut, Storrs, CT, USA. 3. 3 Department of Pathology, Immunology and Laboratory Medicine, Southeast Center for Integrated Metabolomics, Gainesville, FL, USA. 4. 4 School of Nursing, Virginia Commonwealth University, Richmond, VA, USA. 5. 5 Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, Poznan, Poland. 6. 6 Department of Biostatistics, College of Public Health and Health Professions, College of Medicine, University of Florida, Gainesville, FL, USA. 7. 7 Virginia Commonwealth University, Richmond, VA, USA.
Abstract
Many women with breast cancer experience symptoms of pain, fatigue, and depression, collectively known as psychoneurologic (PN) symptoms, during and after chemotherapy treatment. Evidence that inflammatory dysfunction related to cancer and its treatments contributes to the development and persistence of PN symptoms through several interrelated pathways is accumulating. However, a major limiting factor in more precisely identifying the biological mechanisms underlying these symptoms is the lack of biological measures that represent a holistic spectrum of biological responses. Metabolomics allows for examination of multiple, co-occurring metabolic pathways and provides a systems-level perspective on biological mechanisms that may contribute to PN symptoms. METHODS: In this pilot study, we performed serum metabolome analysis using liquid chromatography high-resolution mass spectrometry of global and targeted metabolomics from the tryptophan pathway from archived samples from 19 women with early-stage breast cancer. We used paired t tests to compare metabolite concentrations and Pearson's correlation coefficients to examine concomitant changes in metabolite concentrations and PN symptoms before and after chemotherapy. RESULTS: Levels of pain, fatigue, and depression increased after chemotherapy. Compared with pre-chemotherapy, global metabolites post-chemotherapy were characterized by higher concentrations of acetyl-l-alanine and indoxyl sulfate and lower levels of 5-oxo-l-proline. Targeted analysis indicated significantly higher kynurenine levels and kynurenine/tryptophan ratios post-chemotherapy. Symptoms of pain and fatigue had strong associations with multiple global and several targeted metabolites. CONCLUSION: Results demonstrated that metabolomics may be useful for elucidating biological mechanisms associated with the development and severity of PN symptoms, specifically pain and fatigue, in women with early-stage breast cancer.
Many women with breast cancer experience symptoms of pain, fatigue, and depression, collectively known as psychoneurologic (PN) symptoms, during and after chemotherapy treatment. Evidence that inflammatory dysfunction related to cancer and its treatments contributes to the development and persistence of PN symptoms through several interrelated pathways is accumulating. However, a major limiting factor in more precisely identifying the biological mechanisms underlying these symptoms is the lack of biological measures that represent a holistic spectrum of biological responses. Metabolomics allows for examination of multiple, co-occurring metabolic pathways and provides a systems-level perspective on biological mechanisms that may contribute to PN symptoms. METHODS: In this pilot study, we performed serum metabolome analysis using liquid chromatography high-resolution mass spectrometry of global and targeted metabolomics from the tryptophan pathway from archived samples from 19 women with early-stage breast cancer. We used paired t tests to compare metabolite concentrations and Pearson's correlation coefficients to examine concomitant changes in metabolite concentrations and PN symptoms before and after chemotherapy. RESULTS: Levels of pain, fatigue, and depression increased after chemotherapy. Compared with pre-chemotherapy, global metabolites post-chemotherapy were characterized by higher concentrations of acetyl-l-alanine and indoxyl sulfate and lower levels of 5-oxo-l-proline. Targeted analysis indicated significantly higher kynurenine levels and kynurenine/tryptophan ratios post-chemotherapy. Symptoms of pain and fatigue had strong associations with multiple global and several targeted metabolites. CONCLUSION: Results demonstrated that metabolomics may be useful for elucidating biological mechanisms associated with the development and severity of PN symptoms, specifically pain and fatigue, in women with early-stage breast cancer.
Entities:
Keywords:
breast cancer; chemotherapy; metabolomics; psychoneurologic symptoms
Authors: Hyong Jin Cho; Jonathan Savitz; Robert Dantzer; T Kent Teague; Wayne C Drevets; Michael R Irwin Journal: J Psychosom Res Date: 2017-05-22 Impact factor: 3.006
Authors: Karsten Suhre; Christa Meisinger; Angela Döring; Elisabeth Altmaier; Petra Belcredi; Christian Gieger; David Chang; Michael V Milburn; Walter E Gall; Klaus M Weinberger; Hans-Werner Mewes; Martin Hrabé de Angelis; H-Erich Wichmann; Florian Kronenberg; Jerzy Adamski; Thomas Illig Journal: PLoS One Date: 2010-11-11 Impact factor: 3.240
Authors: Angela R Starkweather; Debra E Lyon; R K Elswick; Alison J Montpetit; Yvette Conley; Nancy L McCain Journal: Curr Pharmacogenomics Person Med Date: 2013-09
Authors: M-L Lindbohm; E Kuosma; T Taskila; P Hietanen; K Carlsen; S Gudbergsson; H Gunnarsdottir Journal: Psychooncology Date: 2013-12-18 Impact factor: 3.894
Authors: Janice S Withycombe; Ronald Eldridge; Yan Jin; Haiwai Gu; Sharon M Castellino; Dorothy D Sears Journal: Biol Res Nurs Date: 2022-04-25 Impact factor: 2.318
Authors: Hongjin Li; Tingting Liu; Lacey W Heinsberg; Mark B Lockwood; Derek A Wainwright; Min Kyeong Jang; Ardith Z Doorenbos Journal: Biol Res Nurs Date: 2020-06-30 Impact factor: 2.522
Authors: Velda J Gonzalez-Mercado; Sara Marrero; Josué Pérez-Santiago; Maribel Tirado-Gómez; Miguel A Marrero-Falcón; Elsa Pedro; Leorey N Saligan Journal: P R Health Sci J Date: 2021-03 Impact factor: 0.600